Oxiracetam is a synthetic "racetam" drug related to piracetam. It has been used as a medicine in some countries for thinking problems after brain injury, stroke or dementia. It is not approved by FDA in the US.
Also known as: L-oxiracetam, racetam, ISF 2522.
There is no FDA-approved oxiracetam product. Trials used 800 mg twice a day for 12 weeks in dementia (Bottini 1992) and 6 g a day after brain injury (Liu 2025). These are study protocols, not a recommendation.
Oxiracetam is not FDA approved: we found no oxiracetam product in Drugs@FDA. In a 2023 debarment order, FDA described a seller of "nootropics" whose imported products, including oxiracetam, FDA had identified as unapproved new drugs and misbranded drugs; the owner was convicted of a felony and barred from importing drugs for 5 years (Federal Register 2023).
What studies show: in a 2025 phase 3 trial in China (590 people with mild-to-moderate brain injury), L-oxiracetam (one mirror-image form of the molecule) improved thinking scores over 90 days more than placebo and more than standard oxiracetam (Liu 2025). In a 2026 Korean trial in 500 people at high risk of thinking problems after a stroke, 36 weeks of oxiracetam did not prevent decline; the authors say this supports Korea's recent decision to suspend its use (Lim 2026). An older 12-week dementia trial in 65 people found better quality-of-life and some test scores (Bottini 1992).
Safety: serious side effects were no more common than placebo in the 2025 trial (Liu 2025). Products sold online as nootropics are not checked by FDA for content or purity.
We could not find a single published half-life or time to peak for oxiracetam that applies to a supplement dose, so we do not list one. There is no FDA label to check one against.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator